SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:research.chalmers.se:c0179640-3c00-4977-a982-48d895fc3679"
 

Sökning: onr:"swepub:oai:research.chalmers.se:c0179640-3c00-4977-a982-48d895fc3679" > Usefulness of a Nan...

  • Sigfridsson, Kalle,1964Chalmers tekniska högskola,Chalmers University of Technology (författare)

Usefulness of a Nanoparticle Formulation to Investigate Some Hemodynamic Parameters of a Poorly Soluble Compound

  • Artikel/kapitelEngelska2011

Förlag, utgivningsår, omfång ...

  • Elsevier BV,2011

Nummerbeteckningar

  • LIBRIS-ID:oai:research.chalmers.se:c0179640-3c00-4977-a982-48d895fc3679
  • https://research.chalmers.se/publication/192879URI
  • https://doi.org/10.1002/jps.22440DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Drug solubility is an important issue when progressing investigational compounds into clinical candidates. The present paper describes the development and characterization of a nanosuspension that was formulated to overcome problems with poor water solubility and possible adverse events caused by cosolvent mixtures, using ticagrelor as a model compound. A homogeneous nanosuspension of ticagrelor was formed using a wet milling approach, which yielded particle sizes around 230 nm. The nanosuspensions were chemically stable for at least 10 months at both room temperature and when refrigerated, and physically (i.e., particle size) stable for at least 10 months under refrigeration, and approximately 3 years at room temperature and when frozen. One rat model and two dog models were used to assess the pharmacokinetics and hemodynamic-related effects following intravenous administration of nanoparticles. There were no biologically consistent or dose-dependent effects of the nanoparticles on the hemodynamic parameters tested, that is, heart rate, mean aortic pressure, cardiac output, left femoral artery blood flow, or cardiac inotropy (measured as max dP/dt). In conclusion, a stable ticagrelor nanosuspension formulation was developed, suitable for intravenous administration. At the doses evaluated, this formulation was without hemodynamic effects in three sensitive preclinical models. (C) 2010 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:2194-2202, 2011

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Bjorkman, J. A.AstraZeneca AB (författare)
  • Skantze, P.AstraZeneca AB (författare)
  • Zachrisson, H.AstraZeneca AB (författare)
  • Chalmers tekniska högskolaAstraZeneca AB (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Pharmaceutical Sciences: Elsevier BV100:6, s. 2194-22021520-60170022-3549

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy